Mitotech S.A.

Mitotech S.A.
Mitotech S.A.

Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of predominantly age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondria targeting cardiolipin peroxidation inhibitors. Company’s lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases. Mitotech successfully initiated a Phase 2b/3 clinical study for Dry Eye indication in the U.S. with other indications also approaching clinical stage of development.

Stories by Mitotech S.A.